1. Home
  2. CLST vs MAIA Comparison

CLST vs MAIA Comparison

Compare CLST & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catalyst Bancorp Inc.

CLST

Catalyst Bancorp Inc.

HOLD

Current Price

$15.03

Market Cap

54.6M

Sector

N/A

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.21

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLST
MAIA
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6M
44.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
CLST
MAIA
Price
$15.03
$1.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.6K
446.4K
Earning Date
01-22-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.60
N/A
Revenue
$11,340,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$25.23
N/A
Revenue Growth
133.67
N/A
52 Week Low
$10.67
$0.87
52 Week High
$15.30
$2.74

Technical Indicators

Market Signals
Indicator
CLST
MAIA
Relative Strength Index (RSI) 68.54 56.19
Support Level $15.00 $1.07
Resistance Level $15.00 $1.46
Average True Range (ATR) 0.09 0.12
MACD -0.04 0.04
Stochastic Oscillator 95.56 62.71

Price Performance

Historical Comparison
CLST
MAIA

About CLST Catalyst Bancorp Inc.

Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: